BioCatalystWatch
SVAWorkspace / SVA / OverviewCompany library
Price
Market cap
Next catalystExpected 2026Influenza Vaccine (Split Virion), Inactivated (MDCK Cell) · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

PCV13

Pneumococcus (13-valent)

PreINDP1P2P3FilingApproved

Influenza virus

Technology Summary

Clinical

Upcoming clinical milestones

PCV13

Pneumococcus (13-valent)

PreINDP1P2P3FilingApproved

Influenza virus

Other pipelines

HFMD4

EV71 × CA16 × CA10 × CA6

PreINDP1P2P3FilingApproved
Sinovac-QIV

Influenza A/H1N1 × Influenza A/H3N2 × Influenza B/Victoria × Influenza B/Yamagata

PreINDP1P2P3FilingApproved
HmAb-TT

Tetanus toxin

PreINDP1P2P3FilingApproved

Approved / commercial

Influenza A (H1N1)

Influenza A (H1N1)

Approved

PreINDP1P2P3FilingApproved

Seasonal influenza antigens

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Influenza A (H5N1)

Approved

PreINDP1P2P3FilingApproved

Sabin-strain poliovirus

Approved

PreINDP1P2P3FilingApproved

History / paused

SARS-CoV-2 S1-RBD

Approved

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

SVA PR & News

PR & News

SVA SEC archive